Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [Leu5]Enkephalin SCHEMBL17951964 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL631958 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL11399380 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL631959 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL30857 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL16189980 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL25236888 | 0.93 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL30400052 | 0.93 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| SCHEMBL14241976 | 0.92 | OPRD1 (0.65) | OPRD1OPRM1OPRK1 | |
| SCHEMBL12962865 | 0.92 | OPRD1 (0.65) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | claimed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | claimed |
| US-20250333436-A1 | Aqueous Solid Phase Peptide Synthesis | POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) | 2025-10-30 | — | — | US | disclosed |
| EP-4370528-A1 | AQUEOUS SOLID PHASE PEPTIDE SYNTHESIS | Polypeptide Laboratories Holding (PPL) AB (SE) | 2024-05-22 | — | — | EP | disclosed |
| CN-117897392-A | Aqueous solid phase peptide synthesis | 多肽实验室(PPL)控股公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023287345-A1 | AQUEOUS SOLID PHASE PEPTIDE SYNTHESIS | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022107049-A1 | ANTINOCICEPTIVE COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333436-A1 | Aqueous Solid Phase Peptide Synthesis | SPPL2B, ASNS, MAX | OPRD1 2051/4885OPRM1 2109/4885OPRK1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.